Can Ubrogepant Be Given With Tryptomer or Propranolol for Migraine?
Yes, ubrogepant can be safely co-administered with both triptans (like sumatriptan/tryptomer) and propranolol for migraine treatment, with no clinically significant drug interactions or safety concerns identified.
Co-Administration with Triptans
Ubrogepant can be used together with triptans without safety concerns. The FDA label for ubrogepant explicitly states that "no significant pharmacokinetic interactions were observed for either ubrogepant or co-administered drugs when UBRELVY was administered with...sumatriptan" 1.
A dedicated Phase 1 pharmacokinetic study demonstrated that when ubrogepant 100 mg and sumatriptan 100 mg were co-administered 2:
- Ubrogepant's time to peak concentration was delayed (3 hours vs 1.5 hours) and maximum concentration reduced by 24%
- Sumatriptan's overall exposure (AUC) and peak concentration showed no significant changes
- Most importantly: No treatment-emergent adverse events occurred with co-administration in the Phase 1 study
- In Phase 3 trials, participants who took ubrogepant plus a triptan as rescue medication had similar adverse event rates (12.8%) compared to ubrogepant alone (14.9%)
Clinical Application
The 2025 American College of Physicians guidelines position these medications in a treatment algorithm 3:
- First-line: Start with NSAIDs or acetaminophen
- Second-line: Add a triptan to NSAID/acetaminophen if inadequate response
- Third-line: Consider gepants (including ubrogepant) for patients who "do not tolerate or have inadequate response to combination therapy of a triptan and an NSAID or acetaminophen" 3
The guidelines explicitly allow for combination use, as they recommend patients can take "a second dose of study medication or rescue medication" including triptans between 2-48 hours after initial treatment 3.
Co-Administration with Propranolol
Propranolol is a beta-blocker commonly used for migraine prevention. While the provided evidence doesn't include specific pharmacokinetic studies of ubrogepant with propranolol, the FDA label indicates that ubrogepant is not metabolized by or does not significantly interact with the major pathways that would be affected by propranolol 1.
Key pharmacologic considerations:
- Ubrogepant is primarily metabolized by CYP3A4 and is a substrate of P-gp and BCRP transporters 1
- Propranolol does not significantly inhibit CYP3A4 or these transporters
- The FDA label states that "age, sex, race, and body weight did not have a significant effect on the pharmacokinetics" of ubrogepant 1, suggesting minimal interaction potential with common preventive medications
Important Caveat
One older review mentions a theoretical pharmacodynamic interaction between triptans and propranolol through vasoconstrictive mechanisms 4, but this applies to triptan-propranolol combinations, not ubrogepant-propranolol. Ubrogepant works via CGRP receptor antagonism, not vasoconstriction, making this concern irrelevant for ubrogepant.
Practical Recommendations
For acute treatment with preventive therapy:
- Continue propranolol as prescribed for prevention
- Use ubrogepant 50-100 mg for acute migraine attacks as needed
- If ubrogepant alone is insufficient, a triptan can be added or used as rescue 2-24 hours later
Medication overuse headache warning: Be aware that triptans have a lower threshold for medication overuse headache (≥10 days/month) compared to NSAIDs (≥15 days/month) 3. The threshold for gepants is still being established, but frequent episodic migraine may warrant adding or optimizing preventive medications 3.
Cost consideration: The guidelines recommend prescribing "less costly recommended medications" 3, so if triptans plus NSAIDs provide adequate relief, they should be tried before advancing to gepants, which are typically more expensive.